A Phase IIa, Multi-centre, Randomized, Double-Blind, Double-Dummy, Active and Placebo Controlled, Parallel Group Study to Assess the Effectiveness and Safety of AZD2066 After 6 Weeks of Treatment in Patients With Major Depressive Disorder - D0475C00020.

Trial Profile

A Phase IIa, Multi-centre, Randomized, Double-Blind, Double-Dummy, Active and Placebo Controlled, Parallel Group Study to Assess the Effectiveness and Safety of AZD2066 After 6 Weeks of Treatment in Patients With Major Depressive Disorder - D0475C00020.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2012

At a glance

  • Drugs AZD 2066; Duloxetine
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jan 2011 Planned End Date changed from 1 Jan 2011 to 1 Nov 2010 as reported by ClinicalTrials.gov.
    • 15 Oct 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 25 Jun 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top